founded in Beijing, China, in 1999 with the mission to become a premier scientific partner for the global research community. The goal of BGI is to make leading-edge genomic science highly accessible, which it achieves through its investment in infrastructure, leveraging the best available technology, economies of scale, and expert bioinformatics resources. BGI, and its affiliates, BGI Americas and BGI Europe, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, supporting a variety of disease, agricultural, environmental, and related applications.
BGI has a proven track record of excellence, delivering results with high efficiency and accuracy for innovative, high-profile research: research that has generated over 170 publications in top-tier journals such as Nature and Science. BGI's many accomplishments include: sequencing one percent of the human genome for the International Human Genome Project, contributing 10 percent to the International Human HapMap Project, carrying out research to combat SARS and German deadly E. coli, playing a key role in the Sino-British Chicken Genome Project, and completing the sequence of the rice genome, the silkworm genome, the first Asian diploid genome, the potato genome, and, more recently, have sequenced the human Gut Metagenome, and a significant proportion of the genomes for the1000 Genomes Project,
For more information about BGI, please visit http://www.genomics.cn
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN and SEQCAP are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact:
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Page: 1 2 3 4 Related biology technology :1
|SOURCE Roche Diagnostics GmbH|
Copyright©2010 PR Newswire.
All rights reserved
. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche2
. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche3
. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration4
. Roche completes acquisition of ARIUS5
. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics6
. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List7
. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board8
. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.9
. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients10
. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash11
. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors